#USA #Seattle #Biotech Industry #Greg Kunst #Aurion Biotech

Greg Kunst's Pinnacle Recognition in the Biotech Field

On April 4, 2025, Greg Kunst was featured prominently in the Inner Circle, receiving acknowledgment as a Pinnacle Professional Member Inner Circle of Excellence. This honor highlights his significant contributions and leadership in the biotech industry, showcasing his commitment to innovation and improving global health.

With over 20 years of experience, Kunst is currently the president and CEO of Aurion Biotech. His tenure there since 2021 has solidified his reputation in the field, thanks to his strategic insights and visionary leadership, which have driven impactful advancements in patient care. Furthermore, he also serves on the board of Pr3vent Inc. since 2023, and as a strategic advisor at Oculogica since 2019, further demonstrating his broad influence across multiple organizations.

Kunst's educational background is impressive. He earned a Bachelor of Science in Economics from Brigham Young University in 2002, followed by an MBA in General Management and Strategy from Vanderbilt University's Owen Graduate School of Management in 2006. He has also completed esteemed programs, including the Novartis Advance Program in Strategy and Communications and the M2 Leadership Program at Novartis.

Throughout his career, Kunst has been a driving force behind numerous accomplishments. Notably, he successfully raised $132 million for Aurion Biotech over a three-year period. Additionally, his efforts expanded Glaukos Corporation's revenue from zero to $300 million, elevating its presence to over 20 countries. Currently, he is focused on developing a groundbreaking cell therapy aimed at tackling corneal blindness, highlighting his unwavering commitment to improving global health outcomes.

Kunst’s affiliations with prestigious organizations such as the Ophthalmic World Leaders and the American-European Congress of Ophthalmic Surgery showcase his dedication to professional excellence. His leadership and innovative spirit have earned him numerous honors and accolades, further emphasizing his status as a visionary in the biotech landscape.

Looking forward, Kunst is poised for continued success, committed to advancing patient care and bolstering public health within the biotech industry. His relentless drive for innovation will undoubtedly shape the future of healthcare for many generations to come.

For media inquiries, please contact Katherine Green at 516-825-5634 or via email at [email protected].